TrialBreast cancer research : BCR2025

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.

Morgane Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.